# AtriCure

Type: Company (ATRC)

Source: GetYourBrief — https://getyourbrief.com/entity/atricure
Canonical HTML page: https://getyourbrief.com/entity/atricure

## Recent coverage (4 stories, network-wide)

### DAFNA Capital Trims Axogen Stake Following 71% Rally and 20% Revenue Growth
2026-03-22 04:25:41 · Sector: bio · Sentiment: Neutral · Impact: 5/10 · Sources: 2

DAFNA Capital Management reduced its position in Axogen by approximately $6.5 million during the fourth quarter of 2025, a move that follows a significant 71% surge in the company's stock price. Despite the trim, Axogen remains a significant holding for the fund as the company continues to see 20% revenue growth driven by its peripheral nerve repair portfolio.
Full story: https://getbiobrief.com/story/dafna-capital-trims-axogen-stake-71-surge

### DAFNA Capital Trims Axogen Stake Amid 71% Stock Surge and Strong Revenue Growth
2026-03-22 04:25:06 · Sector: health · Sentiment: Neutral · Impact: 5/10 · Sources: 2

DAFNA Capital Management reduced its position in Axogen by approximately $6.5 million during the fourth quarter of 2025, following a period of significant outperformance. Despite the trim, Axogen remains a core holding for the fund as the medical device maker continues to capitalize on its 20% revenue growth and dominant position in the peripheral nerve repair market.
Full story: https://gethealthbrief.com/story/dafna-capital-axogen-trim-analysis

### Corporate Resilience Shines as IAMGOLD and EQT Lead Multi-Sector Earnings Beats
2026-02-18 19:20:10 · Sector: finance · Sentiment: Positive · Impact: 6/10 · Sources: 6

A diverse group of mid-to-large cap companies across mining, energy, and healthcare reported stronger-than-expected quarterly results, signaling robust operational efficiency. IAMGOLD and EQT Corporation headlined the session with significant revenue outperformance, reflecting strength in commodity and energy markets.
Full story: https://getfinancebrief.com/story/iamgold-eqt-earnings-beats-february-2026

### MedTech Resilience: Insulet and AtriCure Outperform Q4 Earnings Expectations
2026-02-18 19:19:07 · Sector: bio · Sentiment: Positive · Impact: 6/10 · Sources: 6

Insulet and AtriCure reported strong quarterly results, both beating analyst estimates on top and bottom lines. These results highlight robust demand for insulin delivery systems and atrial fibrillation treatments despite broader macroeconomic pressures.
Full story: https://getbiobrief.com/story/medtech-earnings-insulet-atricure-q4-2026

---
This page is a machine-readable summary. Sentiment measures the directional read of each development for this entity, not the tone of the reporting; impact weights consequence, not syndication reach. See https://getyourbrief.com/guides/methodology for the full editorial methodology.